Bayer HealthCare has announced that Eylea ( Aflibercept solution for injection ) has been approved by the European Commission ( EC ) for the treatment of visual impairment due to macular edema seconda ...

Regeneron has announced that detailed one-year results from the VIEW 1 and VIEW 2 phase 3 studies of Aflibercept ( Eylea ) injection, published in the journal Ophthalmology.
Eylea, for the treatmen ...

All three commonly used TNF blockers ( Infliximab, Etanercept and Adalimumab ) were initially approved for the treatment of rheumatoid arthritis, and were subsequently approved for a number of other s ...

Eylea ( Aflibercept ) injection has been recommended for approval by the European Committee for Medicinal Products for
Human Use ( CHMP ) for the treatment of visual impairment due to macular edema s ...

The purpose of a study was to evaluate the effect of monthly intravitreal Ranibizumab ( Lucentis ) on hard exudate ( HE ) area and the impact of hard exudate on visual acuity ( VA ) outcomes in diabet ...